The distribution of pharmacogenetic variation observed in this diverse cohort of Canadian pediatric IBD patients supports the utility of both TPMT and NUDT15 genotyping to provide the best care possible for patients in advance of thiopurine treatment. This evidence concerns the gene TPMT and inflammatory bowel disease.